Franck Rahaghi, MD

Appointed
2003

Additional Training

• Enhancing Team Effectiveness, professional development program for health professions faculty, jointly sponsored by the Association of American Medical Colleges and Harvard Medical School
• Cleveland Clinic Leadership Course, Cleveland Clinic, 2006
• Advanced Training in Quality, American College of Executive Physicians

Professional Highlights

• Expert in pulmonary hypertension, serving South Florida (Broward and Palm Beaches)
• Head of the first comprehensive Pulmonary Education Department
• Chair of Quality in Cleveland Clinic Florida, advancing outcome-based improvements in quality

Certifications

• Internal Medicine - Pulmonary Disease
• Internal Medicine - Critical Care Medicine

Specialty Interests

pulmonary hypertension, Alpha-1 anti-trypsin deficiency/COPD, interstitial lung diseases, including: collagen vascular diseases (Scleroderma) and pulmonary fibrosis, Sarcoidosis, critical care

Awards & Honors

• Innovator Award, Cleveland Clinic, for innovation in medical technology, 2005-2007
• Leadership Certificate, Cleveland Clinic (promising future leaders at Cleveland Clinic), 2006
• Fellow, American College of Chest Physicians, 2005
• Cornell Award for Best Fellow Research, 2004

Innovations & Patents

• Convertible dual-lumen endotracheal tube: U.S. Patent Pending, 2005

Memberships

• College of Chest Physicians
• Society of Critical Care Medicine
• Pulmonary Hypertension Association/Research
• American Medical Association
• American Society of Executive Physicians,Vanguard Member

See publications for Franck Rahaghi, MD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 1/18/2023, Dr. Rahaghi has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Rahaghi receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

• United Therapeutics Corporation
• Ani Pharmaceuticals, Inc.
• Janssen Pharmaceuticals, Inc.
• Mallinckrodt, plc
• Takeda Pharmaceuticals North America, Inc.
• Boehringer Ingelheim

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.